New Hybrids of Quipazine and Trazodone as Selective Inhibitors of Uptake of 5-Hydroxytryptamine
作者:Abdulqader A. Alhaider
DOI:10.1002/jps.2600810120
日期:1992.1
Two new congeners, 4-(chloropropyl)-1-(2-quinolyl)piperazine- and 2-[3-[4-[2-(quinolyl)]-1-piperazinyl]propyl]-1,2,4-triazolo] 4,3-a]pyridin-3(2H)-one, of trazodone were synthesized and found to be potent and selective inhibitors of synaptosomal uptake of 5-hydroxytryptamine [5-HT, serotonin; IC50 = norepinephrine greater than 5 microM, 5-HT = 210-890 nM], with minimal effects in antagonizing (-)-apomorphine-induced
两个新的同类物,4-(氯丙基)-1-(2-喹啉基)哌嗪-和2- [3- [4- [2- [喹啉基] -1-哌嗪基]丙基] -1,2,4-三唑合成了曲唑酮的4,3-a]吡啶-3-3(2H)-one,是5-羟色胺[5-HT,5-羟色胺; 5-羟色胺]的突触体吸收的有效和选择性抑制剂。IC50 =大于5 microM的去甲肾上腺素,5-HT = 210-890 nM],在拮抗(-)-阿扑吗啡诱导的爬山行为和抑制小鼠的自发运动活性方面作用最小(ED50大于50 mg / kg)。这两种化合物的行为类似于非典型的抗抑郁药,因为它们弱拮抗利血平诱导的体温过低。急性毒性研究表明,与丙咪嗪或喹嗪相比,这些化合物的致死性更低。此外,长期治疗(20 mg / kg,每天持续10天和21天)显着降低了异丙肾上腺素诱导的大鼠大脑皮层中环AMP的增加,表明β-肾上腺素受体的脱敏。这些发现表明,这些化合物作为潜在的抗抑郁药,与特定的血清素能机制有关。